Related Experiment Video
Updated: Dec 7, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
MEK inhibition with trametinib is a successful therapy in ganglioglioma
Eliza Baird Daniel1,2, Douglas E Ney3, Jean M Mulcahy Levy1,2
1Department of Pediatrics, University of Colorado Denver, Aurora, USA.
Abstract:
Gangliogliomas are predominantly low-grade primary brain tumors comprised of neuronal and glial components that are found in both pediatric and young adult populations. In the majority of cases, surgical resection of these tumors is curative. However, tumor location in eloquent centers of the brain can make surgical intervention inappropriate. Additionally, a subset of tumors progress to anaplastic ganglioglioma which carries a poor prognosis, despite resection. Activating mutations in the MAPK pathway, such as BRAF V600E, have been identified in many of these tumors. Tumors carrying such mutations have demonstrated susceptibility to MEK inhibition therapy. However, there remains a subset of ganglioglioma that do not contain a known mutation in the MAPK pathway and thus have not been targeted with MEK inhibition therapy. Here, we present a young adult ganglioglioma patient without identified MAPK pathway activation mutations who demonstrated a significant and sustained response to MEK inhibition with trametinib.
Insights
This study highlights a young adult
Area of Science:
- Neuro-oncology
- Molecular biology
- Genetics
Background:
- Gangliogliomas are primary brain tumors with neuronal and glial cells, typically low-grade and treatable with surgery.
- Some gangliogliomas progress to anaplastic types or occur in critical brain areas, complicating treatment.
- Activating MAPK pathway mutations, like BRAF V600E, are found in some gangliogliomas and respond to MEK inhibitors.
Purpose of the Study:
- To investigate the efficacy of MEK inhibition in a ganglioglioma patient lacking MAPK pathway mutations.
- To present a case study of novel therapeutic response in a challenging subset of brain tumors.
Main Methods:
- Case report of a young adult ganglioglioma patient.
- Genetic analysis to identify MAPK pathway mutations.
- Treatment with trametinib (a MEK inhibitor).
- Monitoring of tumor response and patient outcomes.
Main Results:
- The patient's ganglioglioma lacked identified MAPK pathway activation mutations.
- The patient showed a significant and sustained response to trametinib treatment.
- This suggests potential efficacy of MEK inhibition beyond known MAPK mutations.
Conclusions:
- MEK inhibition may be a viable therapeutic option for gangliogliomas without MAPK pathway mutations.
- This finding expands potential treatment strategies for refractory or inoperable gangliogliomas.
- Further research is warranted to explore MEK inhibition in this patient population.
More Related Videos
09:17Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
Published on: September 16, 2019
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021